Markets Edge — Capital flows, CMO moves, M&A

ISABELLA'S ISLAY Capital Markets Apr 19, 2:01 AM EDT

JPMorgan Chase

The Block ↗

JPMorgan projects $130B crypto inflows in 2025, accelerating into 2026

JPMorgan expects crypto inflows to rise further in 2026 after record $130 billion in 2025, signaling sustained institutional adoption.

ReadingInstitutional capital has shifted from skepticism to allocation. Firms waiting for permission from their risk committees just set their entry point.

WatchThe first $500B+ sovereign wealth fund announcement into crypto. Within 12 months.

Read full analysis → Original ↗

cryptoinstitutional-capital2026-outlookbtc

HENRI IV M&A Intelligence Apr 19, 2:01 AM EDT

Gilead Sciences

Business Wire ↗

Gilead completes Arcellx acquisition with all regulatory approvals secured

Gilead Sciences has received all required regulatory approvals for its acquisition of Arcellx and extended its tender offer, completing a major cell therapy consolidation.

ReadingLarge pharma is consolidating cell therapy talent and IP before valuations reset. Mid-cap founders should read this as their timeline just compressed by 24 months.

WatchBluebird Bio, Adicet Bio, or another CAR-T platform announces a sale within 90 days at a marked-down valuation.

Read full analysis → Original ↗

m&apharmacell-therapyconsolidation

MACALLAN 1926 Financial Intelligence Apr 19, 2:01 AM EDT

Morgan Stanley

Intellectia AI ↗

Morgan Stanley launches Bitcoin ETF at 0.14% fee, undercuts market

Morgan Stanley introduced its MSBT Bitcoin ETF with a 0.14% fee, positioning itself as the cheapest crypto fund option in the market.

ReadingWhen major banks launch loss-leader crypto products, retail adoption accelerates on their distribution. The fee war is done; the volume race begins.

WatchGoldman Sachs and BNY Mellon announce their own sub-0.20% Bitcoin products within 60 days.

Read full analysis → Original ↗

cryptoetfpricingmorgan-stanley

LOUIS XIII Capital Markets Apr 19, 2:01 AM EDT

Scholastic Corporation

PR Newswire ↗

Scholastic authorizes $200M share buyback in capital return signal

Scholastic Corporation announced a cash tender offer to purchase up to $200 million of its common stock, signaling confidence in valuation and returning capital to shareholders.

ReadingEducational publishing is consolidating around a smaller TAM. Buybacks signal resignation to flat-line growth, not confidence in upside.

WatchPearson or Houghton Mifflin Harcourt announce their own buyback within the next quarter.

Read full analysis → Original ↗

capital-returnbuybackscholasticeducation

PAPPY 23 M&A Intelligence Apr 19, 2:01 AM EDT

Agero / Urgent.ly

Stock Titan ↗

Agero launches tender offer for Urgent.ly at $5.50 per share

The buyer of roadside assistance service Agero has launched a tender offer to take Urgent.ly (NASDAQ: ULY) private at $5.50 per share.

ReadingPublic markets are exiting fragmented service verticals. The $5.50 price is a signal for every other niche roadside/mobility player: this is your new ceiling.

WatchClass-action litigation from Urgent.ly shareholders challenging the fairness of $5.50. Filed within 30 days.

Read full analysis → Original ↗

m&atender-offerroadside-assistgoing-private

JOHNNIE BLUE Venture Intelligence Apr 19, 2:01 AM EDT

Crypto Market (Institutional)

TradingView / openPR ↗

Institutional crypto flows hit $1.1B+ in single week; XRP gains favor

Bitcoin and crypto fund inflows accelerated to $1.1 billion as institutional investors, particularly through XRP-favored vehicles ($224M flows), shift capital into digital assets.

ReadingInstitutional crypto capital is no longer monolithic. Single-token preference signals suggest winners and losers forming inside the institutional allocation bucket.

WatchFund-level announcements from top-10 asset managers explicitly stating XRP or single-token weighting strategies. Next 45 days.

Read full analysis → Original ↗

crypto-flowsinstitutionalxrpbtc

WELL POUR Venture Intelligence Apr 19, 2:01 AM EDT

Lisata Therapeutics / Kuva Labs

TradingView ↗

Lisata Therapeutics reports Kuva Labs seeking refinancing; tender offer delayed

Lisata Therapeutics disclosed that Kuva Labs is seeking new financing and that the tender offer previously announced has not yet commenced, signaling potential capital challenges.

ReadingLisata's ability to fund Kuva through 2026 is now a question. This is the moment venture investors begin due diligence on contingency plans.

WatchLisata announces either a capital injection into Kuva or a revised valuation for the tender offer within 60 days. The announcement itself reveals Lisata's cash position.

Read full analysis → Original ↗

financingventuretender-offerlisata